162 related articles for article (PubMed ID: 38424530)
1. Effects of triple therapy on disease burden in patients of GOLD groups C and D: results from the observational COPD cohort COSYCONET.
Zader JA; Jörres RA; Mayer I; Alter P; Bals R; Watz H; Mertsch P; Rabe KF; Herth F; Trudzinski FC; Welte T; Kauczor HU; Behr J; Walter J; Vogelmeier CF; Kahnert K
BMC Pulm Med; 2024 Mar; 24(1):103. PubMed ID: 38424530
[TBL] [Abstract][Full Text] [Related]
2. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
4. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242
[TBL] [Abstract][Full Text] [Related]
5. COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort.
Kellerer C; Kahnert K; Trudzinski FC; Lutter J; Berschneider K; Speicher T; Watz H; Bals R; Welte T; Vogelmeier CF; Jörres RA; Alter P
Respir Med; 2021; 185():106461. PubMed ID: 34116329
[TBL] [Abstract][Full Text] [Related]
6. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
7. Overuse of long-acting β
Brunton SA; Hogarth DK
Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
[TBL] [Abstract][Full Text] [Related]
8. EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS.
Buhl R; Dreher M; Mattiucci-Guehlke M; Emerson-Stadler R; Eckhardt S; Taube C; Vogelmeier CF
Adv Ther; 2023 Jul; 40(7):3263-3278. PubMed ID: 37256536
[TBL] [Abstract][Full Text] [Related]
9. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
10. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
11. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.
Suissa S; Dell'Aniello S; Ernst P
COPD; 2022 Dec; 19(1):1-9. PubMed ID: 34544314
[TBL] [Abstract][Full Text] [Related]
12. Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B
Czira A; Banks V; Requena G; Wood R; Tritton T; Wild R; Compton C; Ismaila A
BMJ Open; 2024 Feb; 14(2):e072361. PubMed ID: 38326272
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β
Czira A; Requena G; Banks V; Wood R; Tritton T; Castillo CM; Yeap J; Wild R; Compton C; Rothnie KJ; Herth F; Quint JK; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2023; 18():643-659. PubMed ID: 37155496
[TBL] [Abstract][Full Text] [Related]
14. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
15. DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.
Singh D; Litewka D; Páramo R; Rendon A; Sayiner A; Tanni SE; Acharya S; Aggarwal B; Ismaila AS; Sharma R; Daley-Yates P
Adv Ther; 2023 Oct; 40(10):4282-4297. PubMed ID: 37382864
[TBL] [Abstract][Full Text] [Related]
16. Variation in costs due to virtual switching from free- to fixed-triple LABA/LAMA/ICS combinations among COPD patients: an analysis using a primary care database.
Lapi F; Marconi E; Lombardo FP; Micheletto C; Cricelli C
Curr Med Res Opin; 2022 Nov; 38(11):1997-2001. PubMed ID: 36154352
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
18. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study.
Monteagudo M; Nuñez A; Barrecheguren M; Miravitlles M
Arch Bronconeumol; 2022 Oct; 58(10):699-707. PubMed ID: 35618580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
